Literature DB >> 15334048

Transmission of donor illness by stem cell transplantation: should screening be different in older donors?

D Niederwieser1, C Gentilini, U Hegenbart, T Lange, P Moosmann, W Pönisch, H Al-Ali, M Raida, P Ljungman, A Tyndall, A Urbano-Ispizua, H M Lazarus, A Gratwohl.   

Abstract

With increasing donor age, the potential of transmitting diseases from donor to recipient reaches new dimensions. Potentially transmittable diseases from donors include infections, congenital disorders, and acquired illnesses like autoimmune diseases or malignancies of hematological or nonhematological origin. While established nonmalignant or malignant diseases might be easy to discover, early-stage hematological diseases like CML, light-chain multiple myelomas, aleukemic leukemias, occult myelodysplastic syndromes and other malignant and nonmalignant diseases might not be detectable by routine screening but only by invasive, new and/or expensive diagnostic tests. In the following article, we propose recommendations for donor work-up, taking into consideration the age of the donors. In contrast to blood transfusions, stem cells from donors with abnormal findings might still be acceptable for HCT, when no other options are available and life expectancy is limited. This issue is discussed in detail in relation to the available donor and stem cell source. Finally, the recommendations presented here aim at harmonized worldwide work-up for donors to insure high standard quality.

Entities:  

Mesh:

Year:  2004        PMID: 15334048     DOI: 10.1038/sj.bmt.1704588

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

Review 1.  G-CSF in Healthy Allogeneic Stem Cell Donors.

Authors:  Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-22       Impact factor: 3.747

2.  The impact of improved JACIE standards on the care of related BM and PBSC donors.

Authors:  C Anthias; M E Ethell; M N Potter; A Madrigal; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-11-10       Impact factor: 5.483

3.  Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

Authors:  Robbie G Majzner; Huzefa Mogri; Ravi Varadhan; Patrick Brown; Kenneth R Cooke; Javier Bolaños-Meade; Lode Swinnen; Jennifer Kanakry; Leo Luznik; Richard J Jones; Ephraim Fuchs; Rich Ambinder; Yvette Kasamon; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-01-03       Impact factor: 5.742

4.  Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres.

Authors:  Paola Coluccia; Giovanni Crovetti; Claudia Del Fante; Franco Maria Dallavalle; Daniele Laszlò; Piero Ferremi; Daniele Marenchino; Luca Santoleri; Concetto De Filippo; Flavia Mattana; Luigi Mariani; Paolo Perseghin; Fernando Ravagnani
Journal:  Blood Transfus       Date:  2012-07-12       Impact factor: 3.443

Review 5.  Risks and mechanisms of oncological disease following stem cell transplantation.

Authors:  Sergey V Anisimov; Asuka Morizane; Ana S Correia
Journal:  Stem Cell Rev Rep       Date:  2010-09       Impact factor: 5.739

6.  A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.

Authors:  Hideki Mitsui; Norimitsu Saito; Atsushi Satake; Tsuyoshi Nakazawa; Takahiro Karasuno; Akira Hiraoka
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 7.  Hematopoietic stem cell donation.

Authors:  Shu-Huey Chen; Tso-Fu Wang; Kuo-Liang Yang
Journal:  Int J Hematol       Date:  2013-02-19       Impact factor: 2.490

8.  Severe events in donors after allogeneic hematopoietic stem cell donation.

Authors:  Joerg Halter; Yoshihisa Kodera; Alvaro Urbano Ispizua; Hildegard T Greinix; Norbert Schmitz; Geneviève Favre; Helen Baldomero; Dietger Niederwieser; Jane F Apperley; Alois Gratwohl
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

Review 9.  Sixty as the new forty: considerations on older related stem cell donors.

Authors:  P Anderlini
Journal:  Bone Marrow Transplant       Date:  2016-08-08       Impact factor: 5.483

10.  Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalities.

Authors:  Matthew P Tilson; Richard J Jones; Amy Sexauer; C A Griffin; Laura A Morsberger; Denise A S Batista; Donald Small; Kathleen H Burns; Christopher D Gocke; Milena Vuica-Ross; Michael J Borowitz; Amy S Duffield
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-13       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.